IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy
Purpose: This study aimed to investigate the potential association between IDH mutation and O-6-methyl-guanine methyl transferase (MGMT) gene promoter methylation and pseudoprogression disease (psPD) in glioblastoma multiforme (GBM) patients after concurrent temozolomide (TMZ)-based chemoradio-therapy. Methods: A total of 157 GBM patients who received concurrent TMZ-based chemoradiotherapy were included in this retrospective study. The association between psPD and a number of demographic and genetic factors, including IDH mutation and MGMT promoter methylation, were analyzed based on logistic regression, Cox regression, and multivariate analysis. Results: Of the 157 GBM patients, 145 (92.36%) patients, including 38 patients with psPD, 38 patients with early progression (ePD), and 69 patients with non-progression (non-PD), were followed up for six to 56 months. We identified a higher rate of MGMT promoter methylation and IDH1 mutation in psPD patients compared with ePD patients (P = 0.002). In addition, MGMT promoter methylation and IDH1 mutation predicted a high probability of psPD development in GBM patients (P = 0.001 and P < 0.001, respectively). MGMT promoter methylation, IDH1 mutation, Karnofsky performance score (KPS) >= 70, and psPD were associated with a significantly longer overall survival of GBM patients (P = 0.001, 0.001, 0.002, and P < 0.001, respectively). Both of MGMT promoter methylation and IDH mutation had a cumulative effect on the OS of GBM patients. GBM patients with psPD (39.2 +/- 2.1 months, P < 0.001) had a longer median survival (MS) than GBM patients with ePD (11.9 +/- 1.1 months) or with non-PD (24.4 +/- 2.4 months). Conclusion: MGMT promoter methylation and IDH1 mutation were associated with PsPD and predicted a longer median survival in GBM patients after TMZ-based chemoradiotherapy. Genetic analyses of the MGMT promoter and IDH1 may allow us to effectively treat GBM patients. (C) 2016 Elsevier B.V. All rights reserved.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81572899]
第一作者机构：[1]Navy Gen Hosp, Dept Neurosurg, Beijing 100048, Peoples R China;
通讯作者：
通讯机构：[3]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, 6 Tiantan Xili, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714)：
Li Hailong,Li Jiye,Cheng Gang,et al.IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy[J].CLINICAL NEUROLOGY AND NEUROSURGERY.2016,151:31-36.doi:10.1016/j.clineuro.2016.10.004.
APA：
Li, Hailong,Li, Jiye,Cheng, Gang,Zhang, Panning&Li, Xuezhen.(2016).IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.CLINICAL NEUROLOGY AND NEUROSURGERY,151,
MLA：
Li, Hailong,et al."IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy".CLINICAL NEUROLOGY AND NEUROSURGERY 151.(2016):31-36
